SCHEMBL4849696

SCHEMBL4849696

C=CCc1c(F)cnc2ccc(OC)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 7/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
ALOX12 P18054 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTR1A P08908 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CCNB2 O95067 1/20 0.38
CDK1 P06493 1/20 0.38
CCNB1 P14635 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4849713 0.86 KCNH2 (0.43) KCNH2ALDH1A1HTR1AADRA1DADRA1A
SCHEMBL5813519 0.85 KCNH2 (0.43) KCNH2HTR1AADRA1DADRA1AADRA1B
SCHEMBL4854654 0.84 SRC (0.41) ALDH1A1TP53CYP3A4ALOX15TSHR
SCHEMBL27579215 0.82 KCNH2 (0.46) KCNH2HTR1AADRA1DADRA1AADRA1B
SCHEMBL2535928 0.82 KCNH2 (0.43) KCNH2HTR1AADRA1DADRA1AADRA1B
SCHEMBL2533923 0.82 KCNH2 (0.46) KCNH2HTR1AADRA1DADRA1AADRA1B
SCHEMBL6267955 0.80 KCNH2 (0.48) KCNH2LMNA
SCHEMBL2954867 0.79 KDM4E (0.42) ALDH1A1TP53HTR1AADRA1DADRA1A
SCHEMBL14249652 0.76 KDM4E (0.42) ALDH1A1TP53CYP3A4ALOX15TSHR
SCHEMBL4851061 0.75 ROCK2 (0.44) KCNH2TSHRMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348434-B2 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them BIGOT ANTONY 2008-03-25 US disclosed
EP-1654252-A2 SUBSTITUTED QUINOLINES SERVING AS ANTIMICROBIAL AGENTS NOVEXEL (FR) 2006-05-10 EP disclosed
WO-2005016916-A2 SUBSTITUTED QUINOLINES SERVING AS ANTIMICROBIAL AGENTS NOVEXEL (FR) 2005-02-24 WO disclosed
US-20050032800-A1 4-Substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them AVENTIS PHARMA S. A. (FR) 2005-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032800-A1 4-Substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them CBR3, HRH2, HRH4 KCNH2 272/4885ALDH1A1 2345/4885TP53 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.